Photobiomodulation (PBM), also known as low-level laser therapy (LLLT), represents a non-invasive therapeutic approach that utilizes red to near-infrared light (600-1000 nm) to modulate cellular function and promote neuroprotection. This modality has gained significant attention in recent years for its potential applications in treating neurodegenerative diseases including Alzheimer's disease and Parkinson's disease [@garcia2025].
The fundamental principle underlying PBM involves the absorption of light by cellular chromophores, primarily cytochrome c oxidase (COX) in the mitochondrial electron transport chain. This absorption triggers a cascade of photochemical and photophysical events that enhance cellular metabolism, reduce oxidative stress, and modulate inflammatory responses [@hamburger1979; @karu1999].
Photobiomodulation is characterized by specific physical parameters that determine its biological effects:
| Parameter |
Optimal Range |
Clinical Significance |
| Wavelength |
600-1000 nm |
Penetration depth and chromophore absorption |
| Power density |
1-100 mW/cm² |
Energy delivery and thermal effects |
| Fluence |
1-50 J/cm² |
Total energy dose per treatment |
| Pulse structure |
Continuous or pulsed |
Tissue-specific responses |
| Treatment duration |
30 seconds to 30 minutes |
Acute vs chronic protocols |
The primary mechanism involves light absorption by mitochondrial cytochrome c oxidase (COX), also known as Complex IV. This absorption leads to:
- Enhanced electron transfer and ATP production [@passarella1994]
- Increased reactive oxygen species (ROS) at sub-lethal levels, triggering adaptive cellular responses
- Modulation of signaling pathways including cAMP, Ca²⁺, and nitric oxide (NO)
- Activation of transcription factors such as Nrf2 and NF-κB [@quirk2018]
PBM exerts significant effects on cortical pyramidal neurons and interneurons:
- Metabolic enhancement: Increased mitochondrial ATP production and improved neuronal viability
- Synaptic plasticity: Enhanced long-term potentiation (LTP) and memory formation
- Neuroprotection: Reduced excitotoxicity and apoptotic cell death
- Gene expression: Upregulation of brain-derived neurotrophic factor (BDNF) and other neuroprotective proteins
The hippocampus is particularly responsive to PBM due to its high metabolic demand and vulnerability to neurodegeneration:
- Memory enhancement: Improved performance in spatial memory tasks
- Neurogenesis: Promotion of hippocampal neural stem cell proliferation
- Synaptic plasticity: Enhanced hippocampal LTP and synaptic strength
- Amyloid effects: Preliminary evidence suggests reduced amyloid-beta toxicity [@saltmarche2017]
¶ Retinal and Optic Nerve Neurons
PBM has demonstrated effects on visual system neurons:
- Direct light penetration through the retina
- Photoreceptor mitochondrial support
- Optic nerve axonal protection
- Potential for glaucoma and AMD applications
In Parkinson's disease, PBM may protect the vulnerable dopaminergic neurons of the substantia nigra:
- Reduced alpha-synuclein aggregation
- Mitochondrial dysfunction mitigation
- Neuroinflammation modulation
- Motor function improvement in animal models [@berman2017]
The primary photoacceptor in PBM is cytochrome c oxidase (COX), a mitochondrial enzyme critical for oxidative phosphorylation:
- Photoexcitation: Light absorption at specific wavelengths (primarily 670-850 nm) triggers electronic transitions in the binuclear copper center (Cu_A) and heme a3 of COX
- Enhanced electron transfer: Improved efficiency of the electron transport chain
- ATP production: Increased mitochondrial ATP synthesis via enhanced coupling efficiency
- Oxygen consumption: Modulated cellular oxygen utilization [@karu1999]
PBM induces adaptive mitochondrial responses:
- Mitochondrial membrane potential: Enhanced ΔΨ_m
- Calcium homeostasis: Improved mitochondrial calcium buffering
- Apoptosis regulation: Reduced cytochrome c release and caspase activation
- mtDNA protection: Enhanced repair mechanisms
PBM exhibits biphasic dose-response (Arndt-Schulz curve):
- Low doses: Acute increase in ROS serves as signaling molecules
- Moderate doses: Enhanced antioxidant enzyme expression (SOD, catalase, glutathione peroxidase)
- High doses: Potential oxidative damage
PBM modulates nitric oxide (NO) biology:
- Release of NO from COX, improving local blood flow
- NO as signaling molecule in neuroplasticity
- Dose-dependent effects on NO synthase activity
PBM increases cellular cAMP levels, activating protein kinase A (PKA):
- CREB phosphorylation and gene transcription
- Memory consolidation enhancement
- Synaptic plasticity modulation
Intracellular calcium dynamics are modulated by PBM:
- Enhanced calcium influx through voltage-gated channels
- Improved mitochondrial calcium handling
- Calmodulin activation and downstream effects
PBM activates the MAPK/ERK pathway:
- Cell survival signaling through MEK/ERK
- Neurotrophic factor expression
- Synaptic plasticity enhancement
¶ NF-κB and Nrf2 Pathways
Dual modulation of inflammatory and antioxidant responses:
- NF-κB: Attenuated pro-inflammatory signaling in microglia
- Nrf2: Enhanced antioxidant response element (ARE) activation
PBM shows promise for Alzheimer's disease treatment through multiple mechanisms:
Cognitive Enhancement
- Improved memory and executive function in mild cognitive impairment (MCI) [@chauncey2023]
- Reduced hippocampal atrophy progression
- Enhanced cerebral blood flow
Amyloid-Targeting Potential
- Reduced amyloid-beta aggregation in preclinical models
- Enhanced amyloid clearance mechanisms
- Inhibition of amyloid-induced neurotoxicity
Neuroinflammation Reduction
- Decreased pro-inflammatory cytokines (IL-1β, TNF-α)
- Modulated microglial activation toward anti-inflammatory (M2) phenotype
- Reduced neuroinflammation-associated neuronal damage
Clinical Trials
- Transcranial PBM (tPBM) in mild to moderate AD: Mixed results but generally positive trends
- Combination approaches (tPBM + intranasal) under investigation
Parkinson's disease represents a key target for PBM:
Motor Symptoms
- Improved Unified Parkinson's Disease Rating Scale (UPDRS) scores
- Reduced bradykinesia and rigidity
- Enhanced gait parameters
Neuroprotection
- Preserved dopaminergic neurons in animal models
- Reduced alpha-synuclein pathology
- Mitochondrial function enhancement
Clinical Evidence
- Randomized double-blind trial: Combined transcranial and intra-oral PBM showed significant improvements [@bullock2021]
- Multiple pilot studies demonstrating safety and preliminary efficacy
- Home-use device studies in progress [@darwent2014]
¶ Stroke and Traumatic Brain Injury
PBM has shown promise in neurological recovery:
- Enhanced neural plasticity and rehabilitation outcomes
- Reduced neuroinflammation
- Improved cognitive recovery
- Meta-analysis supports efficacy in post-stroke recovery [@lapchak2016]
¶ Depression and Anxiety
Emerging evidence for psychiatric applications:
- Prefrontal cortex modulation
- Neurotrophic effects
- Neuroinflammation reduction
- Limited but promising clinical data
PBM demonstrates an excellent safety profile:
- Non-invasive: No surgical intervention required
- Non-thermal: Properly parameterized applications produce minimal heat
- Well-tolerated: Minimal side effects in clinical trials
- No known carcinogenicity: Extensive safety data
Reported adverse effects are rare and generally mild:
- Headache (transient)
- Visual disturbances (with improper eye protection)
- Skin irritation (device-specific)
- Rare seizure activity (contraindicated in photosensitive epilepsy)
PBM should be avoided in:
- Photosensitive epilepsy
- Active cancer at treatment site
- Pregnancy (abdominal region)
- Active skin infections
- Patients with implanted devices (device-specific)
Key parameters for optimal safety and efficacy:
- Wavelength selection: 810 nm provides optimal tissue penetration
- Power density: Keep below 100 mW/cm² to avoid thermal effects
- Treatment duration: Limit continuous exposure to 30 minutes per site
- Eye protection: Mandatory for transcranial applications
- Laser devices: High-power, point-source delivery
- LED arrays: Broader coverage, lower power density
- Helmets: Whole-brain coverage systems
- Direct delivery to brain tissue via olfactory pathway
- Targeted approach for neurodegenerative diseases
- Transcranial + intranasal for enhanced brain coverage
- Combination with other neuromodulation techniques
¶ Research Challenges and Future Directions
- Variable protocols across studies
- Limited understanding of optimal parameters
- Need for larger, well-designed clinical trials
- Mechanism of action not fully elucidated
- Combination therapies: PBM + pharmacological agents
- Personalized protocols: Parameter optimization based on individual patient characteristics
- Wearable devices: Continuous treatment paradigms
- Novel wavelengths: Exploring other absorption peaks
- Garcia-Castro et al., Transcranial photobiomodulation systematic review (2025)
- Chauncey et al., Photobiomodulation for mild cognitive impairment (2023)
- Saltmarche et al., Significant improvement in cognition with photobiomodulation (2017)
- Mehr et al., Transcranial photobiomodulation for Alzheimer's disease (2021)
- Volpert et al., PBM effects on neuroinflammation (2021)
- Quirk et al., Photobiomodulation and the brain (2018)
- Bullock-Saxton et al., Combined transcranial and intra-oral photobiomodulation for Parkinson's disease (2021)
- Berman et al., Photobiomodulation as a treatment for Parkinson's disease (2017)
- Darwent et al., Photobiomodulation devices for Parkinson's disease (2014)
- Huang et al., Low-level laser therapy and photobiomodulation (2011)
- Montazeri et al., Transcranial photobiomodulation for brain disorders (2021)
- Berman & Nichols, Photobiomodulation for neurodegenerative diseases (2019)
- Lapchak, Transcranial near-infrared laser therapy for stroke (2016)
- Karu, Primary mechanisms of photobiomodulation (1999)
- Passarella, Increase in protonic activity in mitochondria after irradiation (1994)
- Hamburger, Cytochrome oxidase as the primary photoacceptor (1979)